Who are Contineum Therapeutics's investors?

Contineum Therapeutics's investors include Hadean Ventures, Red Tree Venture, Samsara BioCapital, Casdin Capital, Franklin Templeton, JJDC, Sectoral Asset Management, Versant Ventures.

Contineum Therapeutics

NASDAQ: CTNM

Founded 2017 · 59 employees on LinkedIn · 8 known investors

Find your way into Contineum Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Contineum Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Contineum is a biopharmaceutical company developing small molecule drug candidates to treat inflammatory and fibrotic diseases by modulating critical disease pathways. The company is advancing multiple candidates into clinical trials, with a focus on diseases of high unmet medical need.

Biotech Healthtech

Founders & leadership

Carmine StengonePresident and Chief Executive Officer

Peter T. SloverChief Financial Officer

Daniel S. Lorrain Chief Scientific Officer2024–2026Daniel S. Lorrain is Chief Scientific Officer at Contineum Therapeutics, a biopharmaceutical company developing small molecule drug candidates for inflammatory and fibrotic diseases. He has experience leading drug discovery programs across CNS, respiratory, inflammation, and fibrosis from target identification through clinical development.

Timothy R. WatkinsChief Medical Officer and Head of Development

Investors · 8

Hadean Ventureslisted by Hadean VenturesOslo

How we know: Hadean Ventures's portfolio page · funding news · Not right? Tell us

Red Tree Venturelisted by Red Tree VentureSan Diego

Samsara BioCapitallisted by Samsara BioCapitalMenlo Park

How we know: Samsara BioCapital's portfolio page · funding news · Not right? Tell us

Casdin CapitalreportedNew York

How we know: funding news · Not right? Tell us

Franklin TempletonreportedSan Mateo

How we know: funding news · Not right? Tell us

JJDCreportedNew Brunswick · $500K – $5M

How we know: the S-1 prospectus · Not right? Tell us

Sectoral Asset ManagementreportedMontreal

How we know: the S-1 prospectus · funding news · Not right? Tell us

Versant VenturesreportedSan Francisco · $250K – $5M

How we know: the S-1 prospectus · a partner's Signal profile · Not right? Tell us

Related companies · 2

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.

Companies working in the same space as Contineum Therapeutics.

In the news

Contineum Therapeutics schedules a Sept. 15 fireside chat at 5:35 p.m.stocktitan.net · Aug 2026

Frequently asked questions

What does Contineum Therapeutics do?: Contineum is a biopharmaceutical company developing small molecule drug candidates to treat inflammatory and fibrotic diseases by modulating critical disease pathways. The company is advancing multiple candidates into clinical trials, with a focus on diseases of high unmet medical need.
Who are Contineum Therapeutics's investors?: Contineum Therapeutics's investors include Hadean Ventures, Red Tree Venture, Samsara BioCapital, Casdin Capital, Franklin Templeton, JJDC, Sectoral Asset Management, Versant Ventures.